Pharma
-
Getty Images
India’s pharma industry is going global. But can it catch up to China?
A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.
By Kelly Bilodeau • May 13, 2026 -
Getty Images
Why the FDA’s push for real-time clinical trials could favor Big Pharma
The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.
By Alivia Kaylor • May 13, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Permission granted by Sanofi
How tough is it getting for vaccine makers in the U.S.?
As federal policy chills domestic demand, some companies are increasingly leaning on sales from international markets.
By Kelly Bilodeau • May 12, 2026 -
Permission granted by Curium
Sponsored by CuriumWhen reliability becomes patient care in nuclear medicine
Making reliability a clinical imperative can help scale theranostics beyond flagship centers.
By Renaud Dehareng, Group CEO, Curium • May 11, 2026 -
Getty Images
Biotech layoffs are easing, but is the worst over?
BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.
By Kelly Bilodeau • May 8, 2026 -
Permission granted by Novo Nordisk
Novo hikes guidance on Wegovy pill’s fast sales start
Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity pill, the drugmaker said in its most recent earnings report.
By Kristin Jensen • May 7, 2026 -
Justin Sullivan via Getty Images
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.
By Kelly Bilodeau • May 7, 2026 -
Drew Angerer via Getty Images
A new company rises from the ashes of Purdue Pharma
Knoa Pharma will still sell the opioid medications that triggered a national crisis, but with guardrails.
By Kelly Bilodeau • May 6, 2026 -
Mario Tama via Getty Images
What’s at stake in Amgen’s showdown with the FDA?
The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the market, but the large pharma is digging its heels in.
By Meagan Parrish • May 5, 2026 -
Getty Images
Protein degraders gain speed as Arvinas scores landmark approval
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.
By Kelly Bilodeau • May 4, 2026 -
Getty Images
Pfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
By Ben Fidler • April 30, 2026 -
Getty Images
Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
With many pharma companies focused on developing drugs that shed pounds, Biohaven is digging its heels into a clinical program based on an experimental myostatin inhibitor that builds muscle.
By Alivia Kaylor • April 29, 2026 -
Getty Images
As biosimilars gain US traction, patent thickets are under more scrutiny
A 10-year push for more biosimilars in the U.S. has led to a surge in copycat entrants, bringing more attention to the legal barriers.
By Michael Gibney • April 28, 2026 -
Michael M. Santiago via Getty Images
Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point
The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.
By Alexandra Pecci • April 28, 2026 -
Scott Olson via Getty Images
Lilly’s CAR-T devotion; CBER’s next top dog?
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Lilly’s latest CAR-T buyout A push by Eli Lilly to acquire genetic platforms like the multibillion-dollar acquisition of in vivo CAR-T biote...
By PharmaVoice Staff • April 24, 2026 -
Permission granted by Cleveland Diagnostics
Is pharma missing the boat on diagnostics?
Precision medicine is bringing pharma and diagnostics closer together, but there’s still a ways to go before the matchup is fully realized.
By Meagan Parrish • April 24, 2026 -
Michael Gibney/PharmaVoice
HHS, industry leaders spar over drug pricing, TrumpRx and PBMs
Debate about drug costs erupted among prominent healthcare figures, including Dr. Oz, Mark Cuban, Calley Means and PhRMA in Washington, D.C., but they all agreed on one thing: The system is broken.
By Michael Gibney • April 23, 2026 -
Getty Images
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”
By Alexandra Pecci • April 22, 2026 -
Getty Images
Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push
The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as the future of genetic medicines.
By Michael Gibney • April 21, 2026 -
Getty Images
Roche’s DAC investment; Big Pharma’s lavish CEO bumps
Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.
By PharmaVoice Staff • April 17, 2026 -
Getty Images
Can an LSD candidate do for anxiety what Spravato did for depression?
Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a potential approval.
By Meagan Parrish • April 17, 2026 -
Mario Tama via Getty Images
How J&J plans to hit $100B in revenue this year
Johnson & Johnson leaders have laid out a plan to reach record revenue this year while opening the door to more down the road.
By Michael Gibney • April 16, 2026 -
Getty Images
Will cancer drugmakers ever conquer p53?
The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.
By Kelly Bilodeau • April 15, 2026 -
Spencer Platt via Getty Images
5 notable pharma CEO pay hikes in 2025
Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.”
By Alexandra Pecci • April 14, 2026 -
Sedat Suna via Getty Images
The era of Big Pharma’s one-size-fits-all pipeline is fading
Roche, AstraZeneca and Sanofi demonstrate how companies are following their own R&D paths.
By Kelly Bilodeau • April 13, 2026
